Document Detail


A prospective analysis of imatinib-induced c-KIT modulation in ovarian cancer: a phase II clinical study with proteomic profiling.
MedLine Citation:
PMID:  17559139     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: c-Kit and platelet-derived growth factor receptor (PDGFR) are potential molecular targets in epithelial ovarian cancer (EOC). Imatinib inhibits the kinase domain and subsequent downstream signaling of these receptor tyrosine kinases. The objective of this study was to investigate biochemical and biologic effects of imatinib on EOC. METHODS: Patients with recurrent EOC who had received no more than 4 prior regimens and who had good end-organ function were eligible. Imatinib was administered orally at a dose of 400 mg twice daily in continuous, 28-day cycles with reassessment imaging studies obtained every other cycle. Tumor core biopsies were obtained prior to and at 4 weeks into therapy; microdissected tumor and stroma were subjected to protein lysate array analysis. Blood samples were obtained monthly for cytokine measurements. RESULTS: Twenty-three patients were enrolled, including 16 patients who received imatinib 600 mg daily because of gastrointestinal (GI) toxicity and fluid accumulation at the starting dose. The median time to disease progression was 2 months (range, 2-14 months). Common grade 3 toxicities included edema/ascites/pleural effusions in 11 patients (48%), GI complaints in 8 patients (35%), fatigue in 3 patients (13%), and grade 2 and 3 cytopenias in 10 patients and 3 patients (43% and 13%), respectively. Increased circulating levels of interleukin 6 were associated with grade >/=2 fluid collection (P = .02). A statistically significant trend was observed between pretreatment phosphorylated-kit levels in microdissected tumor and stroma and GI toxicity (P < .01), between tumor levels of epidermal growth factor receptor (EGFR) and PDGFR with grade of fatigue (P </= .005), and EGFR and phosphorylated-AKT levels with grade of ascites and edema (P </= .01). CONCLUSIONS: The results of this study indicated imatinib had minimal activity as a single agent in EOC. Its ability to modulate its molecular targets suggests that it may be considered in combinatorial therapy.
Authors:
Edwin M Posadas; Virginia Kwitkowski; Herbert L Kotz; Virginia Espina; Lori Minasian; Nana Tchabo; Ahalya Premkumar; Mahrukh M Hussain; Richard Chang; Seth M Steinberg; Elise C Kohn
Related Documents :
23575469 - Evolution of the techniques of radiation therapy in the management of lymphoma.
24476969 - Evaluation of progression prior to surgery after neoadjuvant chemoradiotherapy with com...
23927849 - Carcinoma of the oral tongue in patients younger than 30 years: comparison with patient...
3166389 - Blast crisis of philadelphia chromosome-positive chronic myelocytic leukemia (cml). tre...
23777659 - Progesterone receptor negativity is an independent risk factor for relapse in patients ...
23235299 - Characterization of sociodemographic and clinicopathological features in brazilian pati...
2206569 - Hypercalcaemia in patients with disseminated breast cancer.
2624799 - Long-term follow-up of operative treatment for pulmonary metastases.
14643819 - Long-term results of pathological stage i non-small cell lung cancer: validation of usi...
Publication Detail:
Type:  Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Intramural    
Journal Detail:
Title:  Cancer     Volume:  110     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-07-09     Completed Date:  2007-09-05     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  309-17     Citation Subset:  AIM; IM    
Affiliation:
Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892-1500, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antineoplastic Agents / adverse effects,  therapeutic use*
Ascites
Cytokines / blood
Female
Humans
Middle Aged
Ovarian Neoplasms / drug therapy*,  metabolism
Piperazines / adverse effects,  therapeutic use*
Prospective Studies
Proteome*
Proto-Oncogene Proteins c-kit / metabolism*
Pyrimidines / adverse effects,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Cytokines; 0/Piperazines; 0/Proteome; 0/Pyrimidines; 152459-95-5/imatinib; EC 2.7.10.1/Proto-Oncogene Proteins c-kit

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Correlates of screening sigmoidoscopy use among men in a large nonprofit health plan.
Next Document:  Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with...